According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “
Separately, DA Davidson upped their target price on shares of USANA Health Sciences from $135.00 to $150.00 and gave the company a neutral rating in a research report on Thursday, July 28th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $149.11.
USANA Health Sciences (NYSE:USNA) opened at 138.35 on Wednesday. The company’s 50-day moving average is $136.09 and its 200-day moving average is $125.61. The stock has a market capitalization of $1.67 billion, a P/E ratio of 18.24 and a beta of 1.16. USANA Health Sciences has a 12 month low of $92.00 and a 12 month high of $142.96.
USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, July 26th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.05 by $0.02. The business had revenue of $258.50 million for the quarter, compared to the consensus estimate of $256.66 million. USANA Health Sciences had a net margin of 10.07% and a return on equity of 34.15%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.92 EPS. Equities analysts anticipate that USANA Health Sciences will post $8.10 earnings per share for the current year.
In related news, insider Deborah Woo sold 5,041 shares of the stock in a transaction that occurred on Thursday, August 18th. The stock was sold at an average price of $131.15, for a total transaction of $661,127.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Guest sold 16,285 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $131.08, for a total value of $2,134,637.80. Following the sale, the insider now directly owns 16,285 shares of the company’s stock, valued at $2,134,637.80. The disclosure for this sale can be found here. 57.00% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the company. BlackRock Institutional Trust Company N.A. boosted its stake in USANA Health Sciences by 15.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 163,822 shares of the company’s stock worth $18,255,000 after buying an additional 22,326 shares during the last quarter. Teachers Advisors Inc. boosted its stake in USANA Health Sciences by 30.6% in the first quarter. Teachers Advisors Inc. now owns 87,383 shares of the company’s stock worth $10,610,000 after buying an additional 20,496 shares during the last quarter. Norges Bank acquired a new stake in USANA Health Sciences during the fourth quarter worth about $8,981,000. Old Mutual Global Investors UK Ltd. boosted its stake in USANA Health Sciences by 174.8% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 59,105 shares of the company’s stock worth $6,586,000 after buying an additional 37,595 shares during the last quarter. Finally, Emerald Acquisition Ltd. acquired a new stake in USANA Health Sciences during the second quarter worth about $4,619,000. 41.86% of the stock is owned by institutional investors and hedge funds.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.